Status:
COMPLETED
Randomized Phase 2 Study of 3 Therapeutic Modalities in PS 2/3 Patients With NSCLC Stage IIIB/IV
Lead Sponsor:
Intergroupe Francophone de Cancerologie Thoracique
Collaborating Sponsors:
AstraZeneca
Sanofi
Conditions:
Carcinoma, Non-Small-Cell Lung
Eligibility:
All Genders
18-80 years
Phase:
PHASE2
Brief Summary
Patients presenting a deterioration of the general state (performance status \[PS\] 2-3), constitute a population which needs an adapted treatment. An analysis was made of the evolution of PS 2 patien...
Detailed Description
Arm A Iressa 250 mg daily PROG/TOX --\> Taxotere 75 mg/m² d1 (d1=d22) Arm B Gemzar 1250 mg/m² d1 \& d8 (d1=d22) PROG/TOX --\> Iressa 250 mg daily Arm C Taxotere 75 mg/m² d1 (d1=d22) PROG/TOX --\> Ir...
Eligibility Criteria
Inclusion
- Inclusion Criteria:
- Stage IIIB/IV NSCLC
- patients with performance status 2 or 3.
Exclusion
Key Trial Info
Start Date :
November 1 2004
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
December 1 2008
Estimated Enrollment :
126 Patients enrolled
Trial Details
Trial ID
NCT00198393
Start Date
November 1 2004
End Date
December 1 2008
Last Update
April 30 2010
Active Locations (2)
Enter a location and click search to find clinical trials sorted by distance.
1
CHU Avicenne - Oncologie
Bobigny, France, 93000
2
CHU Grenoble - pneumologie
Grenoble, France, 38000